Literature DB >> 9255909

Hemolytic uremic syndromes in childhood.

N Gordjani1, A H Sutor, L B Zimmerhackl, M Brandis.   

Abstract

The hemolytic uremic syndrome (HUS) comprises hemolytic anemia, acute renal failure, and thrombocytopenia. It is the most frequent cause of acute renal failure in childhood. Ninety percent of the patients have a diarrheal prodrome, and are referred to as having typical HUS. Approximately 10% exhibit the so-called atypical HUS. Typical HUS is caused by shigatoxin-producing Escherichia coli. The toxin, bound to the globotriosyl ceramide cell receptor and internalized, interferes with protein synthesis, predominantly of endothelial cells. The main target is the kidney, but nearly every organ system can be involved. The most common extrarenal involvement is damage to the central nervous system. The central event is probably an insult to the endothelial cell with consecutive loss of antithrombogenic properties. The von Willebrand factor, activation of platelets via platelet-activating factor, other growth factors (e.g., interleukins 1, 6, 8), nitric oxide, lipopolysaccharides, activated polymorphonucleated neutrophils, and the metabolites of the arachidonic acid cascade (e.g., prostaglandin I2) are believed to be involved in the pathogenic cascade. Controlled therapeutic trials with heparin, dipyridamole, aspirin, and urokinase have not been associated with improved outcome. Antibiotics have not yielded any benefit. Plasma infusions and plasma exchange appear to be efficacious, and are justified in cases of atypical HUS and thrombotic thrombocytopenic purpura. Binding of the toxin to the intestinal lumen, and thereby inhibition of enteral reabsorption, is under investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255909     DOI: 10.1055/s-2007-996101

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

1.  Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Authors:  Masaki Shimizu; Natsumi Inoue; Mondo Kuroda; Hitoshi Irabu; Maiko Takakura; Hisashi Kaneda; Naotoshi Sugimoto; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2017-03-10       Impact factor: 2.801

2.  Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.

Authors:  M Palermo; F Alves-Rosa; C Rubel; G C Fernández; G Fernández-Alonso; F Alberto; M Rivas; M Isturiz
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  Role of nitric oxide in shiga toxin-2-induced premature delivery of dead fetuses in rats.

Authors:  Juliana Burdet; Elsa Zotta; Maximiliano Cella; Ana M Franchi; Cristina Ibarra
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

4.  L-arginine/NO pathway is altered in children with haemolytic-uraemic syndrome (HUS).

Authors:  Nele Kirsten Kanzelmeyer; Lars Pape; Kristine Chobanyan-Jürgens; Dimitrios Tsikas; Hans Hartmann; Anne-Jule Fuchs; Bernhard Vaske; Anibh Martin Das; Marion Haubitz; Jens Jordan; Thomas Lücke
Journal:  Oxid Med Cell Longev       Date:  2014-03-17       Impact factor: 6.543

5.  A case of atypical hemolytic uremic syndrome associated with the c.1273C>T mutation in the complement C3 gene.

Authors:  Hye Jeong Cho; Jung O Kim; Ji Young Huh; Yong Park; Myung-Gyu Kim; Doyeun Oh
Journal:  Blood Res       Date:  2016-09-23

6.  Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.

Authors:  Hae Il Cheong; Sang Kyung Jo; Sung Soo Yoon; Heeyeon Cho; Jin Seok Kim; Young Ok Kim; Ja Ryong Koo; Yong Park; Young Seo Park; Jae Il Shin; Kee Hwan Yoo; Doyeun Oh
Journal:  J Korean Med Sci       Date:  2016-10       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.